FOR IMMEDIATE RELEASE
March 14, 2023
Contact: media@diabetespac.org

Novo Nordisk Latest to Limit Cost-Sharing for People with Diabetes

“More Work to Be Done,” says DLC/DPAC CEO

Washington, D.C. – The Diabetes Leadership Council (DLC) and Diabetes Patient Advocacy Coalition (DPAC) work to ensure quality of and access to care, medications and devices for people living with diabetes; and to educate, inspire and empower patient advocates as well as lawmakers toward meaningful action on diabetes.

We are encouraged by recent announcements by Eli Lilly and Company and Novo Nordisk to limit cost-sharing and list prices on certain insulin products, improving access to a lifeline for many of the 8 million Americans who rely on these medications. But many people will still face gaps in access and affordability, including the uninsured, underinsured, and people on high deductible health plans, who still must face list prices that are out of reach.

“We know that many Americans on high deductible health plans will still face unaffordably high prices for [insulin] products, especially those requiring multiple vials or pens per month,” said George Huntley, CEO of the Diabetes Leadership Council and the Diabetes Patient Advocacy Coalition.

On average, people who use insulin require two to six vials per month; even with today’s announcement, those individuals still face life threatening decisions at the pharmacy counter.

The steps taken by Novo Nordisk and Eli Lilly are positive, but they are not enough. DLC and DPAC continue to fight for transparency in the system, a national insulin copay cap with first dollar coverage, oversight of the PBM rebate system, improved access to biosimilars and equitable access to technology. We applaud the progress achieved and continue to work toward a better life for all people with diabetes.